Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy
Yeo F, Ng C, Loh K, Molassiotis A, Cheng H, Au J, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, Chan A. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Supportive Care In Cancer 2019, 27: 4753-4762. PMID: 30972646, DOI: 10.1007/s00520-019-04771-8.Peer-Reviewed Original ResearchConceptsMinimal clinically important differenceEORTC QLQ-CIPN20QLQ-CIPN20Clinically important differenceDistribution-based approachMotor subscaleNtx subscaleConclusionThe MCIDChange scoresSensory subscaleFunctional Assessment of Cancer Therapy/Gynecologic Oncology Group-NeurotoxicityImportant differenceStandard error of measurementFACT/GOG-NtxNeurotoxic chemotherapyExperience of symptomsAnchor-based approachError of measurementEuropean Organisation of ResearchDistribution-based methodsPeripheral neuropathyChemotherapy-induced peripheral neuropathyMethodsCancer patientsCycles of chemotherapyWorsening peripheral neuropathy